Oncotelic Therapeutics Performance
| OTLCDelisted Stock | USD 0.02 0 6.38% |
The company holds a Beta of -0.0175, which implies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Oncotelic Therapeutics are expected to decrease at a much lower rate. During the bear market, Oncotelic Therapeutics is likely to outperform the market. Oncotelic Therapeutics right now holds a risk of 0.0%. Please check Oncotelic Therapeutics total risk alpha and the relationship between the potential upside and market facilitation index , to decide if Oncotelic Therapeutics will be following its historical price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Oncotelic Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound essential indicators, Oncotelic Therapeutics is not utilizing all of its potentials. The current stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
| Begin Period Cash Flow | 494 K |
Oncotelic |
Oncotelic Therapeutics Relative Risk vs. Return Landscape
If you would invest 2.20 in Oncotelic Therapeutics on September 2, 2024 and sell it today you would earn a total of 0.00 from holding Oncotelic Therapeutics or generate 0.0% return on investment over 90 days. Oncotelic Therapeutics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of otc stocks are less volatile than Oncotelic, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Oncotelic Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Oncotelic Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Oncotelic Therapeutics, and traders can use it to determine the average amount a Oncotelic Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| OTLC |
Based on monthly moving average Oncotelic Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Oncotelic Therapeutics by adding Oncotelic Therapeutics to a well-diversified portfolio.
Oncotelic Therapeutics Fundamentals Growth
Oncotelic OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Oncotelic Therapeutics, and Oncotelic Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Oncotelic OTC Stock performance.
| Return On Equity | 0.5 | ||||
| Return On Asset | -0.13 | ||||
| Current Valuation | 31.34 M | ||||
| Shares Outstanding | 391.11 M | ||||
| Price To Earning | 2.16 X | ||||
| Price To Book | 0.89 X | ||||
| Price To Sales | 8.40 X | ||||
| EBITDA | (8.45 M) | ||||
| Cash And Equivalents | 399.77 K | ||||
| Total Debt | 9.8 M | ||||
| Debt To Equity | 0.40 % | ||||
| Book Value Per Share | 0.06 X | ||||
| Cash Flow From Operations | (4.43 M) | ||||
| Earnings Per Share | 0.02 X | ||||
| Total Asset | 23.61 M | ||||
About Oncotelic Therapeutics Performance
By analyzing Oncotelic Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Oncotelic Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Oncotelic Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Oncotelic Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes and CA4P for the treatment of advanced metastatic melanoma. Oncotelic Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 16 people.Things to note about Oncotelic Therapeutics performance evaluation
Checking the ongoing alerts about Oncotelic Therapeutics for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Oncotelic Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Oncotelic Therapeutics is not yet fully synchronised with the market data | |
| Oncotelic Therapeutics has some characteristics of a very speculative penny stock | |
| Oncotelic Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Oncotelic Therapeutics currently holds 9.8 M in liabilities with Debt to Equity (D/E) ratio of 0.4, which is about average as compared to similar companies. Oncotelic Therapeutics has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Oncotelic Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Oncotelic Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Oncotelic Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Oncotelic to invest in growth at high rates of return. When we think about Oncotelic Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (9.39 M) with profit before overhead, payroll, taxes, and interest of 1.74 M. | |
| Oncotelic Therapeutics currently holds about 399.77 K in cash with (4.43 M) of positive cash flow from operations. | |
| Roughly 56.0% of Oncotelic Therapeutics outstanding shares are owned by corporate insiders |
- Analyzing Oncotelic Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Oncotelic Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Oncotelic Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Oncotelic Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Oncotelic Therapeutics' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Oncotelic Therapeutics' otc stock. These opinions can provide insight into Oncotelic Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Other Consideration for investing in Oncotelic OTC Stock
If you are still planning to invest in Oncotelic Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Oncotelic Therapeutics' history and understand the potential risks before investing.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |